Matthew W. Foehr Purchases 95,000 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr bought 95,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was purchased at an average price of $4.27 per share, with a total value of $405,650.00. Following the transaction, the chief executive officer now owns 2,427,919 shares in the company, valued at approximately $10,367,214.13. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

OmniAb Price Performance

NASDAQ:OABI opened at $4.71 on Wednesday. OmniAb, Inc. has a 12-month low of $2.42 and a 12-month high of $5.97. The firm has a market capitalization of $547.16 million, a P/E ratio of -15.70 and a beta of -0.43. The business has a 50 day simple moving average of $4.92 and a 200 day simple moving average of $4.86.

Analysts Set New Price Targets

Several research analysts have recently commented on OABI shares. Benchmark reiterated a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research report on Friday, August 11th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, OmniAb presently has a consensus rating of “Buy” and an average price target of $10.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC acquired a new position in OmniAb during the 2nd quarter valued at approximately $38,000. Victory Capital Management Inc. bought a new stake in OmniAb during the 2nd quarter valued at $51,000. Chicago Capital LLC bought a new stake in OmniAb during the 2nd quarter valued at $15,959,000. Simplicity Solutions LLC bought a new stake in OmniAb during the 2nd quarter valued at $80,000. Finally, abrdn plc bought a new stake in OmniAb during the 2nd quarter valued at $522,000. Institutional investors and hedge funds own 58.73% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.